Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

Trial Profile

Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2018

At a glance

  • Drugs Triamcinolone (Primary) ; Aflibercept
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms TYBEE
  • Sponsors Clearside Biomedical
  • Most Recent Events

    • 21 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 11 Jun 2018 According to a Clearside Biomedical media release, clinical data from this trial will be presented at the JMP Securities Life Sciences Conference (2018).
    • 31 May 2018 According to the Clearside Biomedical media release, results from this trial will be shared at an upcoming medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top